SCHEMBL2406264

SCHEMBL2406264

N#Cc1nc(-c2cccs2)cnc1N1CCN(C(=O)O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK2 P51955 1/20 0.49
GBA1 P04062 5/20 0.43
ALDH1A1 P00352 10/20 0.42
KDM4E B2RXH2 9/20 0.42
LMNA P02545 7/20 0.42
MAPT P10636 7/20 0.42
HPGD P15428 6/20 0.42
HSD17B10 Q99714 6/20 0.42
TSHR P16473 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
GAA P10253 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
GLA P06280 1/20 0.41
MAPK1 P28482 4/20 0.40
ALOX15 P16050 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2401705 0.85 GBA1 (0.56) NEK2GBA1ALDH1A1KDM4EHPGD
SCHEMBL2403717 0.80 NEK2 (0.52) NEK2GBA1ALDH1A1KDM4ELMNA
SCHEMBL2405278 0.76 NEK2 (0.46) NEK2GBA1ALDH1A1KDM4ELMNA
SCHEMBL2401956 0.75 KDM4E (0.35) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL2402228 0.70 GBA1 (0.41) NEK2GBA1ALDH1A1KDM4ELMNA
SCHEMBL2402537 0.69 GBA1 (0.40) NEK2GBA1ALDH1A1KDM4ELMNA
SCHEMBL2401847 0.68 GBA1 (0.57) NEK2GBA1ALDH1A1KDM4EMEN1
SCHEMBL3763289 0.66 FAAH (0.51) GBA1RAB9ANPC1
SCHEMBL3728232 0.66 KDM4E (0.41) GBA1ALDH1A1KDM4ELMNAMAPT
SCHEMBL20140586 0.66 PARP1 (0.44) ALDH1A1LMNATSHRGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2545058-B1 TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS KALYPSYS INC (US) 2016-08-24 EP disclosed
US-8569300-B2 Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease KALYPSYS INC. (US) 2013-10-29 US disclosed
EP-2545058-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE Kalypsys, Inc. (US) 2013-01-16 EP disclosed
US-20110237565-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-29 US disclosed
WO-2011112766-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237565-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 NEK2 2554/4885GBA1 1531/4885ALDH1A1 2090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.